Evogene
EVGN
24 hedge funds and large institutions have $30.6M invested in Evogene in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0.05% less ownership
Funds ownership: 3.57% → 3.52% (-0.05%)
8% less funds holding
Funds holding: 26 → 24 (-2)
9% less capital invested
Capital invested by funds: $33.6M → $30.6M (-$3M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$321K |
| 2 |
Goldman Sachs
New York
|
+$305K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$39.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$35.8K |
| 5 |
MCM
Moon Capital Management
New York
|
+$27.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$668K |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$318K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$110K |
| 4 |
BOS
Bingham Osborn & Scarborough
San Francisco,
California
|
-$79K |
| 5 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$26.7K |
EVGN Hedge Fund Activity: Q2 2018 in Review
24 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2018, worth a combined $30.6M — down 8.9% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVGN and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was ARK Investment Management, adding an estimated $321K. The largest seller was Morgan Stanley, cutting an estimated $668K.
- 24 institutional investors held Evogene (EVGN) as of Q2 2018, down from 26 in Q1 2018.
- Funds reported $30.6M of Evogene stock for Q2 2018, down 8.9% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q2 2018 and 3 closed out, a net change of -2 holders.
- The largest Evogene buyer in Q2 2018 was ARK Investment Management, an estimated $321K added.
- The largest Evogene seller in Q2 2018 was Morgan Stanley, an estimated $668K sold.
Based on aggregated 13F filings for Q2 2018.